Lithostat

Drug Mission Pharmacal Company
Total Payments
$884,657
Transactions
81
Doctors
57
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $52,558 4 1
2022 $130,946 24 21
2021 $96,453 26 24
2020 $183,545 4 1
2019 $118,703 17 16
2018 $73,923 2 1
2017 $228,529 4 1

Payments by Nature

Nature of Payment Amount Transactions Share
Royalty or License $883,783 23 99.9%
Food and Beverage $873.93 58 0.1%

Top Doctors Receiving Payments for Lithostat — Page 3

Doctor Specialty Location Total Records
, MD Specialist Homewood, IL $11.56 1
, MD Urology Mckinney, TX $11.30 1
, M.D Urology Mc Kinney, TX $11.30 1
, M.D Urology New Haven, CT $11.01 1
, MD Urology Danbury, CT $11.01 1
, MD Urology Danbury, CT $11.01 1
, MD Urology Danbury, CT $11.01 1
«123

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $884,657
  • Total Doctors 57
  • Transactions 81

About Lithostat

Lithostat is a drug associated with $884,657 in payments to 57 healthcare providers, recorded across 81 transactions in the CMS Open Payments database. The primary manufacturer is Mission Pharmacal Company.

Payment data is available from 2017 to 2023. In 2023, $52,558 was paid across 4 transactions to 1 doctors.

The most common payment nature for Lithostat is "Royalty or License" ($883,783, 99.9% of total).